Evaluate the Effect of ALLN-177 in Reducing Urinary Oxalate in Patients With Secondary Hyperoxaluria and Kidney Stones Over 28 Days



Status:Recruiting
Conditions:Nephrology, Nephrology
Therapuetic Areas:Nephrology / Urology
Healthy:No
Age Range:18 - Any
Updated:5/14/2016
Start Date:September 2015
End Date:June 2016
Contact:Annamaria Kausz, MD MS
Email:akausz@allenapharma.com
Phone:617-467-4577

Use our guide to learn which trials are right for you!

A Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients With Secondary Hyperoxaluria and Kidney Stones

Evaluate the safety, tolerability, and efficacy of 28 days of treatment with ALLN-177 for
reducing urinary oxalate excretion in patients with secondary hyperoxaluria and kidney
stones.

This is a multicenter, randomized, double-blind, placebo controlled study to evaluate the
efficacy of ALLN 177 compared with placebo in reducing the urinary excretion of oxalate in
subjects with secondary hyperoxaluria and kidney stones. ALLN-177 is an orally administered
form of oxalate decarboxylase. The goal of therapy with ALLN-177 is to reduce urinary
oxalate excretion by decreasing the absorption of oxalate from the gastrointestinal tract.

Eligible subjects will be randomized to 28 days of treatment with ALLN-177 (7,500 units) or
placebo three times daily with meals. Urinary oxalate excretion will be assessed by 24-hr
urine collections throughout the study.

The study allows for 44 subjects.

Inclusion Criteria:

- History of enteric or idiopathic hyperoxaluria and at least one kidney stone within
the last two years.

Exclusion Criteria:

- Hyperuricemia

- Glomerular filtration rate < 45 mL/min/1.73m2

- Hypercalcemia or hyperthyroidism

- Autoimmune disorder requiring systemic steroids

- Acute renal colic, primary hyperoxaluria, pure uric acid and/or cysteine stones,
renal tubular acidosis, chronic urinary tract infection, or acute renal failure
We found this trial at
11
sites
Cincinnati, OH, Ohio 45212
Principal Investigator: Igor Dumbadze, MD
?
mi
from
Cincinnati, OH, OH
Click here to add this to my saved trials
400 Bald Hill Road
Warwick, Rhode Island 02886
401-739-9350
Principal Investigator: Gyan Pareek, MD
?
mi
from
Warwick, RI
Click here to add this to my saved trials
Garden City, New York 11530
Principal Investigator: Barry Shepard, MD
?
mi
from
Garden City, NY
Click here to add this to my saved trials
Glen Burnie, Maryland 21061
Principal Investigator: Julio Davalos, M.D.
?
mi
from
Glen Burnie, MD
Click here to add this to my saved trials
Lake Success, New York 11042
Principal Investigator: Zeph Okeke, M.D.
?
mi
from
Lake Success, NY
Click here to add this to my saved trials
Mountlake Terrace, Washington 98043
Principal Investigator: Karny Jacoby, MD
?
mi
from
Mountlake Terrace, WA
Click here to add this to my saved trials
New York, New York 10016
Principal Investigator: Jed Kaminetsky, MD
?
mi
from
New York, NY
Click here to add this to my saved trials
Pompano Beach, Florida 33060
Principal Investigator: Craig Herman
?
mi
from
Pompano Beach, FL
Click here to add this to my saved trials
Shreveport, Louisiana 71106
Principal Investigator: Cline Kevin, MD
?
mi
from
Shreveport, LA
Click here to add this to my saved trials
Virginia Beach, Virginia 23462
Principal Investigator: Shaun Wason, MD
?
mi
from
Virginia Beach, VA
Click here to add this to my saved trials
Wilmington, North Carolina 28401
Principal Investigator: Victor Abraham, MD
?
mi
from
Wilmington, NC
Click here to add this to my saved trials